Alivus Life Sciences Limited will participate in an investor and analyst meet scheduled for September 17, 2026. The company confirmed its attendance at the Kotak Healthcare Forum 2026, which will be held in Mumbai.

Event Details

The engagement is structured as an in-person meeting featuring both group and one-on-one sessions. Representatives from Alivus Life Sciences will attend to interact with market participants.

Regulatory Disclosure

The intimation was issued pursuant to Regulation 30 and Para A of Part A of Schedule III of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The disclosure was signed by Rudalf Joseph Corriea, Company Secretary and Compliance Officer, on September 11, 2026.

The schedule and mode of the meeting may change due to exigencies on the part of the investors, analysts, or the company.

Alivus Life Sciences shareholders approved a final dividend of ₹5 per equity share for FY26 and adopted the audited financial statements at the company’s 15th annual general meeting on September 8, 2026. The meeting, conducted via video conferencing, saw all four ordinary resolutions pass with requisite majorities.

The board declared the dividend alongside the approval of financial results for the year ended March 31, 2026. Chairman Hiren Patel presided over the session, which was attended by 38 shareholders representing a significant portion of the voting equity. The company also secured approval for the reappointment of Mr. Hiren Patel as a director retiring by rotation.

Voting Results Breakdown

Shareholder participation was high, with votes cast on over 86% of outstanding shares. The promoter group voted in favor of all resolutions without dissent. Public institutional investors also showed strong support, though some opposition was recorded on the director reappointment resolution.

Shareholder Participation Analysis

The promoter and promoter group held 9,18,96,285 shares and voted in favor of all resolutions with 100% support. Public institutions held 1,57,25,917 shares, with 92.8% of these shares polled. While public institutions unanimously supported the financial statements and dividend, they recorded 9,65,103 votes against the reappointment of Mr. Hiren Patel, accounting for 6.61% of their total vote count.

Public non-institutional shareholders held 1,51,49,246 shares, but only 0.83% of these shares were polled. Despite the low turnout from this segment, the votes cast were overwhelmingly in favor of all agenda items. The scrutinizer, Bhadresh Shah and Associates, confirmed that all resolutions were duly passed under the Companies Act, 2013.